Across more than two decades in pharmaceutical leadership, he has led research, translational medicine, and early development efforts spanning insomnia, schizophrenia, neurodegeneration, and related diseases. He is recognized for leadership roles and for contributions to the discovery and development of suvorexant, the first approved dual orexin receptor antagonist for insomnia, as well as to the approvals of ADHD, fentanyl reversal agent, and others. Dr. Renger is recognized globally for strategic translational medicine leadership: building integrated, decision-driven organizations, linking biology to clinical proof of concept, and advancing programs with innovative mechanistic boldness but disciplined clinical development logic. His work reflects a consistent commitment to creating novel medicines that meaningfully improve patients’ lives.